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Introduction: The aim of this multicenter phase II trial was to
evaluate the combination of oral vinorelbine and cisplatin with
radiotherapy (RT) after cisplatin-docetaxel induction chemotherapy
(CT) in patients with locally advanced non-small cell lung cancer
(NSCLC).
Patients and Methods: Patients with previously untreated, inoper-
able, histologically or cytologically confirmed stage IIIA or IIIB
NSCLC, with performance status 1 and weight loss 10% re-
ceived two cycles of induction CT with cisplatin (75 mg/m2) and
docetaxel (75 mg/m2) every 3 weeks. Patients with a tumor response
or stabilization continued to receive cisplatin (80 mg/m2) and oral
vinorelbine (40 mg/m2) on days 1 and 8 for two cycles, with
concomitant thoracic RT (2 Gy/d, 5 d/wk, and total dose 66 Gy).
Results: Fifty-six patients were enrolled. All patients (n  38) who
received CT-RT were assessable for the tumor response. There were
no complete responses. In the intent-to-treat analysis, the response
rates were 32.1% after induction CT and 41.1% after CT-RT. The
median progression-free and overall survival times were 9.2 months
(95% confidence interval: 7–14) and 20.8 months (95% confidence
interval: 13.7–24.1), respectively. Adverse effects of RT-CT were
grades 3 to 4 neutropenia (four patients) and grade 3 esophageal
toxicity (one patient). No treatment-related deaths occurred.
Conclusion: The oral vinorelbine-cisplatin combination with con-
current RT is feasible and has a favorable risk-benefit ratio in stage
IIIA/IIIB NSCLC.
Key Words: MeSH, Lung neoplasms, Chemoradiotherapy, Oral
vinorelbine.
(J Thorac Oncol. 2011;6: 351–357)
Non-small cell lung cancer (NSCLC) is locally advanced(stages IIIA and IIIB) at diagnosis in approximately one
third of cases. These patients form a highly heterogeneous
group with respect to their clinical status and prognosis.
Apart from a few particular cases in which surgery can be
envisaged either immediately or after neoadjuvant therapy,
the standard treatment is a combination of radiotherapy (RT)
and chemotherapy (CT).1,2 Two recent meta-analyses con-
firmed the superiority of combined RT-CT over thoracic
irradiation alone, with a 5-year survival advantage of 1.7%
with sequential treatment and 2.2% with concurrent treat-
ment.3 Concurrent RT-CT seems to be superior to sequential
treatment, with a survival advantage of approximately 6.6%
at 3 years.4 This advantage seems to be due mainly to better
local tumor control leading to fewer locoregional recurrences
but is somewhat offset by more esophageal toxicity.
Induction CT before concurrent treatment has not been
shown to provide a further survival gain,5 but it has the
theoretical advantages of reducing the tumor volume before
concurrent RT-CT and providing better control of microme-
tastases. It also represents an active treatment pending RT.
In this study, we evaluated induction therapy with
docetaxel-cisplatin, a standard combination used in stage IV
NSCLC.6–8 The Groupe Franc¸ais de Pneumo-Cance´rologie
(GFPC) has previously reported a phase II trial of cisplatin-
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navelbine induction therapy before concurrent docetaxel-
RT.9 The observed efficacy and tolerability of this schedule
justified a trial of a dual-agent combination for both induction
and concurrent CT-RT. The cisplatin-vinorelbine combina-
tion seems to offer the best tolerability profile, while having
similar efficacy to other cytotoxic combinations given con-
currently with RT.10 At equivalent doses based on bioavail-
ability studies, oral vinorelbine has shown similar tumor
response and patient survival rates to intravenous vinorelbine
in previously untreated advanced-stage NSCLC.11,12 When
combined with cisplatin, oral vinorelbine was also effective
for first-line treatment of metastatic disease, showing similar
efficacy to a standard cisplatin-docetaxel combination.13 In
locally advanced disease, a recent international trial demon-
strated the efficacy and acceptable tolerability of oral vinorel-
bine administered during concurrent RT.14
To verify the efficacy and tolerability of the oral vi-
norelbine and cisplatin combination with concomitant RT
after cisplatin-docetaxel induction CT for locally advanced
NSCLC, we conducted a phase II, multicenter trial. The main
endpoint was the response rate. Secondary endpoints were the
time to progression, median overall survival, and tolerability.
PATIENTS AND METHODS
Patient Selection
The main inclusion criteria were as follows: cytologi-
cally or histologically proven NSCLC, inoperable stage IIIA
N2 or stage IIIB, the possibility of including all target sites in
the same radiation field, at least one measurable target,
Eastern Cooperative Oncology Group performance status
1, weight loss less than 10%, age between 18 and 70 years,
no previous CT or RT, life expectancy more than 12 weeks,
normal hepatic function (bilirubin  upper limit of normal
[ULN], SGOT, and/or SGPT 2.5 ULN), normal renal func-
tion (creatinemia  ULN and creatinine clearance 60
ml/min), normal hematologic function (PN 1.5  109/liter,
platelets 100  109/liter and hemoglobin 9.5 g/dl), sat-
isfactory respiratory function (forced expiratory volume in 1
second40% theoretical and PaO260 mm Hg), and written
informed consent.
The main exclusion criteria were unstable heart disease
necessitating treatment (congestive heart failure, effort an-
gina, significant arrhythmia, or history of myocardial infarc-
tion 12 months previously), psychiatric or neurologic dis-
orders, uncontrolled infection, peripheral neuropathy grade
more than 2, definitive contraindications to steroids, allergy
to Polysorbate 80, another past or current malignancy, except
for basocellular skin cancer, treated in situ cervical carci-
noma, or any other malignancy treated with surgery alone,
without relapse for at least 5 years, and catheterized pleural
effusion (regardless of abundance, even in case of negative
cytology).
The pretreatment extension workup consisted of ab-
dominal and thoracic CT, cerebral CT, bone scintigraphy (or
bone radiography), and bronchial endoscopy. (Routine PET
scan was not required, as the trial started before this exami-
nation entered widespread use.)
Treatments
Induction CT
Induction CT consisted of two cycles of cisplatin 75
mg/m2 and docetaxel (Taxotere) 75 mg/m2 given on days 1
and 22 (21-day cycles). The cisplatin and docetaxel doses
could be adjusted according to the results of weekly hema-
tologic tests. Cisplatin and docetaxel could not be adminis-
tered if the neutrophil count was below 1500/mm3 or the
platelet count below 100,000/mm3. In this case, the treatment
was postponed for a week. Growth factors could be given
curatively or as secondary prevention for febrile neutropenia.
The dose could also be adjusted according to the nadir, in
case of peripheral neuropathy or renal or hepatic toxicity.
Concurrent Radio-CT
Chemotherapy. The CT regimen consisted of two cycles of
cisplatin (80 mg/m2, days 1 and 21) and oral vinorelbine (40
mg/m2, days 1, 8, 21, and 28) with day 1 as the first day of
RT. The doses were adjusted according to hematologic and
nonhematologic toxicity. The dose of oral vinorelbine was
halved if the neutrophil or platelet count was between 1000
and 1500/mm3 or between 75,000 and 100,000/mm3, respec-
tively. Treatment was postponed for 8 days if the neutrophil
count was below 1000/mm3 or the platelet count below
75,000/mm3. If treatment had to be postponed twice, the
patient and his/her physician decided whether continued
treatment was warranted.
Radiotherapy. RT began at least 15 days and no more than
3 weeks after the planned end date of cisplatin-docetaxel
induction CT. The target was restricted to the macroscopic
tumor volume and involved nodes. The homolateral supra-
clavicular fossa was treated to 60 Gy, only in patients with
a tumor of the upper lobe or with upper mediastinal
involvement.
The 3D dosimetry was always used, with correction for
heterogeneity and calculation of dose-volume histograms
(planned tumor volume [PTV], lung, marrow, etc.). The
radiation dose was prescribed to the 100% isodose, and the
PTV had to receive at least 95% of the prescribed dose,
following International Commission on Radiation Units and
Measurement recommendations.15 The PTV was defined as
the clinical tumor volume (CTV) plus a safety margin of
approximately 10 to 15 mm. The total dose was 66 Gy,
delivered in 33 fractions over 61⁄2 weeks. To limit the risk of
grade 3 radiation-induced pneumonitis, the total lung vol-
ume receiving 20 Gy had to be less than 30%.16 Spinal cord
dose was kept below 45 Gy.
RT was monitored by weekly gammagraphic verification
or portal imaging. Medical treatment for esophagitis started at
grade 1. If grade 3 acute esophagitis occurred, irradiation was
suspended until symptoms subsided to level 1 of the Radia-
tion Therapy Oncology Group (RTOG) scale. If irradiation
had to be interrupted for more than 15 days, the patient and
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his/her physician decided whether continued treatment was
warranted.
Response and Safety
The tumor response was assessed by a central indepen-
dent panel of oncologists, at the end of induction CT, and 4
weeks after concurrent radio-CT. Complete and partial re-
sponses, stabilization, and progression were defined using
RECIST criteria.17 Patients who progressed after induction
CT left the study, and their subsequent treatment was man-
aged by the investigator. Patients with a tumor response or
stabilization received the concurrent radio-CT. After the end
of the treatment, the patients were seen every 3 months for a
physical examination and chest radiograph, plus any other
examinations the investigator considered necessary. All re-
sponses had to be confirmed at least 1 month later and also
had to be reviewed and confirmed by the independent panel.
Safety was assessed using the National Cancer Institute
Common Toxicity Criteria (2000)18 for CT and the RTOG-
European Organization for Treatment and Research (EORTC)
criteria for RT.19
Statistical Analysis
The required number of patients was calculated with
Fleming’s method,20 as modified by Herndon.21 To avoid
continuing the trial unnecessarily, the working hypothesis
were as follows: in the first study phase, the strategy was to
be rejected if the objective response rate was less than 30%
and was to be tested in a phase III trial if more than 60%; with
a type I risk of 0.02 and a type II risk of 0.10, 15 patients had
to be enrolled in this first phase. If the objective response
rate was between 30% and 60%, the phase II study was to
be continued. Based on the same hypothesis, a further 30
patients had to be recruited, for a total of 45 patients. This
approach avoids the need for a randomized phase II trial.22
To ensure that the strategy was not excessively toxic, we
planned an interim analysis of the results for the first 10
patients who received chemo-RT after induction CT. Tox-
icity would be considered unacceptable if four or more of
these 10 patients had stage  III esophageal or pulmonary
toxicity.
Qualitative variables are reported as frequencies and
percentages and quantitative variables as the mean, median,
and range. Confidence intervals (CIs) were calculated for the
response rate, time to progression, and median survival time
by using Statview software version 5.0. Survival was esti-
mated with the Kaplan-Meier method, the start date being the
date of inclusion.
RESULTS
Characteristics of the Patients
Between March 2006 and May 2007, 60 patients were
selected by 20 centers. Four patients could not be enrolled:
three had stage IV disease and one had a tumor too large for
thoracic RT, as defined in the protocol (Figure 1).
The characteristics of the 56 eligible patients are shown
in Table 1. Median age was 57.4 years, and 87% of the
patients were men. Performance status was 0 in 64.3% of
cases, and the most frequent histologic type was adenocarci-
noma (50%).
At the end of induction CT, seven patients were not
assessable for the tumor response (six because of toxicity and
one death unrelated to the study treatment). Six assessable
patients progressed, one patient was able to have surgery, and
one patient switched centers. Among the patients with tumor
stabilization, three did not receive RT as defined in the
protocol (inappropriate dose or treatment interval). Thus, 38
of the initial 56 patients were able to receive concurrent
chemo-RT, all of whom were assessable for tumor response.
Dose Intensities
During the induction phase, the total doses of cisplatin
and docetaxel actually received were 135  11.9 mg and
135  15.9 mg, respectively, corresponding to dose intensi-
FIGURE 1. Trial flow chart. n, number; CT, chemotherapy;
RT, radiotherapy; RT-CT, radiochemotherapy.
TABLE 1. Characteristics of the Patients (n  56)
n Percentage
Patients included 56
Age (SD) 57.4 (7.9)
Sex (%)
Men 49 87.5
Women 7 12.5
PS (%)
0 36 64.3
1 20 35.7
Histology
Squamous cell 18 32.1
Adenocarcinoma 28 50.0
Large cell 10 17.9
Stages
IIIA 21 37.5
IIIB 35 62.5
Assessable for induction CT 49 87.5
Assessable for RT-CT 38 67.8
RT, radiotherapy; CT, chemotherapy; PS, performance status.
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ties of 98.4% (5.22) for cisplatin and 99% (2.40) for
docetaxel (Table 2). During the chemo-RT phase, the respec-
tive doses of cisplatin and oral vinorelbine were 141  19.1
mg and 137  28 mg, corresponding to dose intensities of
94.3% (13.7) and 95.3% (14.4). The total number of CT
cycles was 1.8  0.40 and 1.9  0.27 for the induction and
concurrent treatment phases, respectively. The mean dose of
radiation received was 64.6  4.53 Gy (95% CI: 63.1–66.0).
Safety
During the induction phase, the main toxicity was
hematologic, with grades 3 to 4 neutropenia in 28.6% of cases
and febrile neutropenia in less than 5%. One death unrelated
to the treatment (because of cardiogenic shock) occurred
during this phase. Six patients experienced severe toxicity
(grade 3), ruling out further study treatment, and consisting
of infections in three cases, and renal failure, docetaxel
hypersensitivity, and heart failure in one case each.
Among the 38 patients who received chemo-RT, four
experienced grades 3 to 4 neutropenia, associated with fever in
two cases. Regarding nonhematologic toxicity (Table 3), 15
patients had symptoms of esophagitis (13 grade 2 and two grade
3). Only one patient had grade 2 pulmonary toxicity (radio-
induced pneumonitis). One patient experienced grade 3 periph-
eral neuropathy. There were no treatment-related deaths. Late-
onset grades 3 to 4 adverse effects consisted of esophageal
stenosis in two patients and radiation-induced pulmonary fibro-
sis of the right upper lobe in one patient (Table 3).
Efficacy
No complete responses were obtained after induction CT
or chemo-RT (Table 4). Partial responses were observed in 18
(32%) patients after induction CT and in 23 (41.1%) patients
after chemo-RT. Among the 38 patients who were able to receive
the full study treatment, the objective response rate was 60.5%.
The first evaluation after concurrent chemo-RT showed
tumor progression in seven patients: it was locoregional in two
cases (including one with neoplastic pericarditis) and distant in
five cases (brain in two patients, adrenal in one patient, bone and
adrenal in one patient, and bone in one patient).
The last survival analysis was done on June 30, 2010. In
the intent-to-treat analysis, the median progression-free survival
TABLE 2. Dose Intensity
Induction CT
(n  56)
Concomitant RT-CT
(n  38)
Mean  SD 95% CI Mean  SD 95% CI
Total number of
cycles
102 — 73 —
Mean number of
cycles/patient
1.80  0.39 1.70–1.9 1.90  0.27 1.80–2.0
Dose intensity (mg)
Cisplatin 135  11.9 133–138 141  19.1 137–146
Docetaxel 135  15.6 132–138 — —
Oral vinorelbine — — 137  28.0 130–143
Mean relative dose
intensity (%)
Cisplatin 98.4  5.22 97–99.4 94.3  13.75 91.2–97.5
Docetaxel 99.0  2.40 98.6–99.5 — —
Oral vinorelbine — — 95.3  14.42 92.0–98.6
RT
Total dose (Gy) — — 64.6  4.53 63.1–66
Number of
fractions
— — 33.2  1.90 32.6–33.8
Observance (%) — — 97.84  6.86 95.6–100
RT, radiotherapy; CT, chemotherapy.
TABLE 3. Nonhematological Toxicity
Grade 2 Grade 3 Grade 4
n Percentage n Percentage n Percentage
Induction CT (n 56)
Alopecia 13 23.2 — — — —
Asthenia 1 1.8 — — — —
Pain 2 3.6 2 3.6 — —
Docetaxel
hypersensitivity
— — — — 1 1.8
Deep vein thrombosis — — 1 1.8 — —
Renal failure 4 7.1 1 1.8 1 1.8
Infectious disease 3 5.3 3 5.3 — —
Pneumonia 4 7.1 — — — —
Arrhythmia. Cardiac
failure
2 3.6 1 1.8 — —
Nausea, vomiting 7 12.5 — — — —
Concurrent RT-CT
(n  38)
Nausea, vomiting 4 10.5 1 2.6 — —
Esophagitis 13 34.2 2 5.3 — —
Jugular vein thrombosis 1 2.6 — — — —
Pneumonia 1 2.6 — — — —
Radiation pneumonitis 1 2.6 — — — —
Radiation induced
pulmonary fibrosis
— — — — 1 2.6
Esophageal stenosis 2 5.3 1 2.6 1 2.6
Peripheral neuropathy — — 1 2.6 — —
Asthenia 4 10.5 1 2.6 — —
RT, radiotherapy; CT, chemotherapy.
TABLE 4. Overall Response Rate and Survival (Intent-to-
Treat Analysis)
After
Induction CT
After Concomitant
RT-CT
Patients 56 56
Response
PR 18 (32.1%) 23 (41.1%)
SD 25 (44.6%) 8 (14.3%)
PD 6 (10.7%) 7 (12.5%)
DCR 43 (76.7%) 31 (55.4%)
NA 7 (12.5%) 18 (32.1%)
Survival (mo)
Progression-free survival (mo) 9.2 (95% CI: 7–14)
Overall survival 20.8 (95% CI: 13.7–24)
PR, partial response; SD, stable disease; PD, progressive disease; DCR, disease
control rate; NA, nonassessable; RT, radiotherapy; CT, chemotherapy.
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time was 9.2 months (95% CI: 7–14), and the median overall
survival time was 20.8 months (95% CI: 13.7–24.1) (Figure 2).
The survival rates at 1 and 2 years were 66.1% (95% CI:
52.1–76.8) and 37.1% (95% CI: 23.3–50.9), respectively.
DISCUSSION
In patients with locally advanced NSCLC, two cycles of
the cisplatin-docetaxel combination, followed by concurrent
chemo-RT with cisplatin and oral vinorelbine, yielded an overall
tumor response rate of 41.1% in the intent-to-treat analysis. The
updated median survival time is 20.8 months, with 1-year and
2-year survival rates of 66.1% and 37.1%, respectively. In a
recent phase II trial, the same cisplatin-oral vinorelbine combi-
nation was used both for induction and for concomitant chemo-
RT.14 The median survival time was similar to that obtained in
this study (23 months), and the 1-year and 2-year survival
rates were 74% and 48%, respectively. In contrast, the overall
response rate was higher (53% in the intent-to-treat analysis),
and there was one complete response. This difference in re-
sponse rates could be explained by the fact that all responses
observed in our study were reviewed by an independent expert
panel, contrary to the study by Krzakowski et al.14 Elsewhere, in
a phase II study conducted by our group (GFPC) and using the
same method of evaluation, Vergnenégre et al.9 reported very
similar response rates to those observed in this study. This latter
study used identical induction CT but single-agent docetaxel for
concurrent chemo-RT. The results of this study are also in
keeping with other recent reports.23–26 Using cisplatin-vinorel-
bine induction with a concomitant RT started on day 4 of cycle
2, Zatloukal et al.23 obtained a median overall survival time of
16.6 months and a progression-free survival time of 11.9
months. Using an induction by two cycles of docetaxel 75
mg/m2 on day 1 and cisplatin 40 mg/m2 on days 1 and 2,
followed by concurrent CT-RT with weekly docetaxel 20
mg/m2 and cisplatin 20 mg/m2, Senan et al.24 obtained a 1-year
survival rate of 63.2%, with good tolerability. In another
study25 using the same combination for induction but at
different doses (docetaxel 40 mg/m2 and cisplatin 40 mg/m2
on days 1, 8, 29, and 36), the median progression-free and
median survival times were 13.4 and 26.8 months, respec-
tively. Finally, with an induction consisting of 3 weekly
cycles of paclitaxel 100 mg/m2 and carboplatin area under the
curve 2, followed by 6 weekly cycles of paclitaxel 60 mg/m2
and carboplatin area under the curve 2 combined with tho-
racic RT, Tell et al.26 obtained in 64 patients a time to
progression and a median overall survival of 8.2 and 15.3
months, respectively.
The somewhat modest tumor response rate obtained in our
study contrasts with the patients’ relatively good overall sur-
vival. Nevertheless, our overall survival analysis did not take the
patients’ poststudy treatment into account. This is one weakness
of our study. There is also a possible selection bias related to the
inclusion of patients in good overall condition and to the over-
representation of adenocarcinomatous tumors, both factors be-
ing associated with better outcome.27
Induction CT before concurrent treatment has not been
shown to provide a further survival gain,5 but it has the theoret-
ical advantages of reducing the tumor volume before concurrent
RT-CT and providing better control of micrometastases. It also
represents an active treatment pending RT but carries a risk of
delaying concurrent treatment and of inducing radioresistance.
We observed a low overall response rate (32.1%) after the two
cisplatin-docetaxel cycles, contrasting with the higher rates re-
ported with the same combination in first-line advanced-stage
NSCLC6 or as induction therapy for potentially operable IIIAN2
NSCLC.28 Another EORTC phase II trial29 using this combina-
tion before radical treatment (surgery or RT) for locally ad-
vanced stage IIIAN2 disease (histologically proven N2) reported
a modest overall response rate (39%), as in our study. The
reasons for these dispregnancies are unclear. Nevertheless, this
combination is highly toxic, with six cases of major toxicity and
six cases of disease progression during induction therapy. More
than 20% of patients might have been cured by first-line treat-
ment. The same combination is also associated with a high risk
of neutropenia.28,29
The choice of the cisplatin-oral vinorelbine combina-
tion and concurrent RT was based partly on the results of the
CALGB 9431 study.10 This randomized phase II trial com-
prised three arms, in which cisplatin was combined with
paclitaxel, vinorelbine, or gemcitabine. The response and
FIGURE 2. Progression-free survival and overall
survival (intent-to-treat analysis).
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survival rates were similar in the three arms, but tolerability
was better in the cisplatin-vinorelbine arm, which seems to
have the best risk-benefit ratio when used in combination
with RT. The main value of the oral form lies in the better
quality of life it procures, avoiding stays in CT units and the
risks associated with intravenous administration; it also re-
quires less hospitalization and lowers treatment costs.30
The choice of cisplatin-based CT during RT may also
partly explain the comparatively good overall survival ob-
served in our study. Two randomized phase II trials, one
American31 and the other Spanish,32 comparing induction and
consolidation, used carboplatin as the standard platinum salt.
Although it is difficult to compare these studies, the median
overall survival rates obtained in the induction arms were
lower than in our population. In addition, a recent meta-
analysis of individual data by Ardizzoni et al.33 suggests that
cisplatin is more effective than carboplatin in terms of both
the response rate and overall survival.
Our results confirm the safety of the cisplatin-oral
vinorelbine combination with concurrent thoracic RT. All the
patients who received concurrent chemo-RT were assessable
for the tumor response, and grade 3 toxicity was relatively
infrequent. The frequency of febrile neutropenia (5%) was
acceptable. Esophagitis and radiation-induced pneumonia
were also infrequent and mainly grade 2 or 3. These rates are
similar to those reported in the literature with an identical
combination.14 Moreover, RT only had to be interrupted in
one of our patients, who recovered within 15 days and was
able to pursue the study treatment. These low complication
rates were obtained even though the dose intensities of oral
vinorelbine and cisplatin were near optimal. Oral vinorelbine-
cisplatin should thus be preferred to other doublets and
especially, cisplatin-docetaxel combination that seems to be
more toxic during concomitant radiation therapy.24 In con-
clusion, in patients with locally advanced NSCLC, this phase
II trial shows that cisplatin-docetaxel induction therapy is
highly toxic and gives only a modest tumor response rate but
that oral vinorelbine cisplatin is well tolerated during concur-
rent RT. These results do not warrant a phase III trial.
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